Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Yervoy/Nivolumab Combo Keying Bristol’s Immuno-Oncology R&D Strategy

This article was originally published in The Pink Sheet Daily

Executive Summary

At the Morgan Stanley Healthcare Conference, recently promoted CSO Francis Cuss spoke about Bristol’s plans to test a combination of Yervoy and nivolumab in a variety of tumor types. The pharma’s near-term goals also center on label expansion for Eliquis and filing the first all-oral combination regimen for hepatitis C in Japan.

You may also be interested in...



As Eliquis Sales Lag, Bristol/Pfizer Take Action

The oral anticoagulant generated just $12 million in sales in its first full quarter since it launched in the U.S., lower than expected. Bristol will increase investment in the brand to drive growth.

Incoming Bristol R&D Chief Cuss Initially Plans To Follow Sigal’s Course Of Action

Long-time senior VP of R&D Francis Cuss will succeed Elliott Sigal as Bristol’s head of R&D on July 1, following a transition period. In an investor call, Cuss indicated no great change in strategy but acknowledged an ongoing need to evolve corporate thinking and capability.

EU Proposes Safe Levels For Iron And Vitamin A

The European Safety Authority is running consultations on its proposals to set safe intake levels from foods, including dietary supplements, for iron and vitamin A. 

Topics

Related Companies

Related Deals

Latest Headlines
See All
UsernamePublicRestriction

Register

PS076352

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel